{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}],"title":"0 Infections"},{"measurements":[{"groupId":"OG000","value":"14"}],"title":"1 Infection"},{"measurements":[{"groupId":"OG000","value":"5"}],"title":"2 Infections"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"The one year significant infection rate (infections requiring medical intervention) after double umbilical cord blood transplant using a novel conditioning regimen of fludarabine/melphalan/low dose total body radiation. The data is shown as the number of significant infections participants experienced during the first year, measured from the start of treatment.","groups":[{"description":"All patients receive same therapy\n\nFludarabine: 30 mg/m2/day IV x 6 days\n\nMelphalan: 100 mg/m2/day IV x 1 day\n\nTotal Body Radiation: 200 cGy on Day 0\n\nCord Blood: 2 cord blood units IV","id":"OG000","title":"Fludarabine/Melphalan/TBI"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The two participants found to be ineligible after being consented and registered were excluded from the analysis.","reportingStatus":"POSTED","timeFrame":"1 Year","title":"Number of Participants With a Clinically Significant Infection","type":"PRIMARY","unitOfMeasure":"Participants"}